Ideaya Biosciences Inc Revenue Growth Rates (IDYA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ideaya Biosciences Inc   (NASDAQ: IDYA)
 

IDYA's Revenue Growth by Quarter and Year

Ideaya Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IDYA/growth
https://api.csimarket.com/api/v1/companies/IDYA/fundamentals
https://api.csimarket.com/api/v1/companies/IDYA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IDYA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.24
2nd Quarter June 8.86
1st Quarter March 6.56
FY 25.66

IDYAs Annual Revenue
Ideaya Biosciences Inc 's Revenue in the fiscal year 2025 $ 218.71 millions
Ideaya Biosciences Inc 's Revenue in the fiscal year 2024 $ 7.00 millions
Ideaya Biosciences Inc 's Revenue in the fiscal year 2023 $ 23.39 millions
Ideaya Biosciences Inc 's Revenue in the fiscal year 2022 $ 50.93 millions
Ideaya Biosciences Inc 's Revenue in the fiscal year 2021 $ 27.94 millions




IDYA Revenue third quarter 2026 Y/Y Growth Comment
Ideaya Biosciences Inc reported drop in Revenue in the third quarter 2026 by -95.07% to $ 10.24 millions, from the same quarter in 2025.
The fall in the third quarter 2026 Ideaya Biosciences Inc 's Revenue compares unfavorably to the Company's average Revenue fall of -11.77%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 199 other companies have achieved higher Revenue growth. While Ideaya Biosciences Inc ' s Revenue meltdown of -95.07% ranks overall at the positon no. 3995 in the third quarter 2026.


IDYA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -95.07 %
2nd Quarter June -
1st Quarter March -
FY   -

Financial Statements
Ideaya Biosciences Inc 's third quarter 2026 Revenue $ 10.24 millions IDYA's Income Statement
Ideaya Biosciences Inc 's third quarter 2025 Revenue $ 207.83 millions Quarterly IDYA's Income Statement


IDYA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 15.6 %
2nd Quarter June 35.06 %
1st Quarter March -39.71 %
FY (Year on Year)   -


Back to IDYA Growth rate Comparisons >> Back to IDYA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #200
Healthcare Sector #572
Overall #3995

Revenue Y/Y Growth Statistics
High Average Low
230.87 % -11.77 % -100 %
(Sep 30 2022)   (Mar 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #200
Healthcare Sector #572
Overall #3995
Revenue Y/Y Growth Statistics
High Average Low
230.87 % -11.77 % -100 %
(Sep 30 2022)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ideaya Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
407.59 % 17.55 % -100 %
(Sep 30 2022)  


IDYA's III. Quarter Q/Q Revenue Comment
Ideaya Biosciences Inc achieved in the III. Quarter 2026 below company average Revenue jump of 15.6% quarter on quarter, to $ 10.24 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the % growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Ideaya Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 317.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #77
Overall #317
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #77
Overall #317
Revenue Q/Q Growth Statistics
High Average Low
407.59 % 17.55 % -100 %
(Sep 30 2022)  


IDYA's III. Quarter Q/Q Revenue Comment
Ideaya Biosciences Inc achieved in the III. Quarter 2026 below company average Revenue jump of 15.6% quarter on quarter, to $ 10.24 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the % in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue quarter on quarter growth. While Ideaya Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 317.


Ideaya Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 36.54
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -84.4 %
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment


Ideaya Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 181
Sector # 531
S&P 500 # 3748
Cumulative Revenue growth Comment


Ideaya Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 181
Sector # 531
S&P 500 # 3748




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IDYA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Sutro Biopharma Inc -6.14%$ -6.138 millions
Zai Lab Limited-6.79%$ -6.794 millions


About Ideaya Biosciences Inc Revenue Growth Rates (IDYA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ideaya Biosciences Inc (CIK 1676725).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-445294
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ideaya Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.